BCR-ABL1 Mbcr and Mbcr Screening Kit

Home Clinical Cancer BCR-ABL1 Mbcr and Mbcr Screening Kit

BCR-ABL1 and Cancer Detection Kit

OncoScreen BCR/ABL1 kit is a research tool utilizing multiplex real-time quantitative RT-PCR to provide simultaneous detection and quantification of BCR/ABL1 fusion transcripts (b2a2 /b3a3, OR e1a2), and ABL1 (an endogenous control). The CR/ABL1 kit is compatible with various commercially available Real-Time PCR Systems. Themultiplexed format of the BCR/ABL1 kit reduces reflex testing by providing quantitation of the three predominant BCR/ABL1 fusion transcripts.

Approximately 95% of cases of Chronic Myeloid Leukemia (CML) and about 35% of Acute Lymphoblastic Leukemia (ALL) are associated with the presence of a t(9;22)(q34;q11) chromosomal translocation (Philadelphia chromosome, Ph). This results in creation of an oncogenic fusion gene between ABL proto-oncogene and BCR on chromosomes 9 and 22, respectively. The breakpoint on chromosome 22 occurs between exons 12 and 16 of the BCR gene, while the breakpoint on chromosome 9 mostly occurs between exons 1 and 2 of the ABL gene.The Major transcripts are called b2a2 and b3a2, which encode for a constitutively active chimeric tyrosine kinase of 210kDa (P210).

The breakpoint on chromosome 22 occurs in the first intron of the BCR gene, and the breakpoint on chromosome 9 occurs between exons 1 and 2 of the ABL gene (e1a2). This joins the minor transcripts exon 1 of BCR to exon 2 of ABL, creating a 190 kDa fusion protein with a constitutively active kinase domain.

BCR-ABL1 and Cancer Detection Kit Features

  • Standardized quantitative protocol for control and fusion gene transcripts
  • Optimal quality control
  • to assure high sensitivity
  • Easy workflow with ready-to-use solutions for “Direct to customer” clinical lab tests
  • Simple reaction setup and data interpretation
  • One-step quantitative detection – no need to perform separate cDNA synthesis and qPCR
  • Results aligned with International control standards included with the kit.
  • Low contamination risk – no post-PCR product handling
  • Fast – results in under 80 minutes after PCR start
  • Multiplexed – Control and target genes assessed in the same reaction
  • includes all the reagent required to perform RNA

One-Step Quantitative RT-PCR

Current guidelines recommend the use of quantitative real-time PCR to detect and quantify BCR-ABL expression before, during, and after IM treatment to assess the minimal residual disease (MRD) in patients with CML and ALL.

This protocol is designed to conform to those guidelines. Our BCR-ABL1 P210 (Mbcr) and P190 (mbcr) screening Kit have been formulated for highly reproducible first-strand cDNA synthesis and subsequent real-time PCR in a single tube. A combination of validated primers, hydrolysis probes, and hot-start DNA polymerase ensures that the kits lead to highly-specific and ultra-sensitive results in a single step.

BCR-ABL1 and Cancer Detection Kit Contents

  • Reagents required for cDNA synthesis and PCR amplification/detection
  • Validated reaction controls
  • Plastic wares for the screening kit

Order Information for BCR-ABL1 and Cancer Detection Kit

# Product Cat. No. Reaction size/kit
1 Oncoscreen BCR-ABL1 Mbcr Quantitative PCR Kit OBBQ25 25
2 Oncoscreen BCR-ABL1 Mbcr Quantitative PCR Kit OBBQ50 50
3 Oncoscreen BCR-ABL Mbcr and mbcr Quantitative PCR kit OBBEQ25 25
4 Oncoscreen BCR-ABL1 Mbcr and mbcr Quantitative PCR kit OBBEQ50 50
5 Oncoscreen BCR-ABL1 Mbcr and mbcr Quantitative PCR kit OBBEQ100 100